SSR 146977

Drug Profile

SSR 146977

Latest Information Update: 17 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Class
  • Mechanism of Action Neurokinin 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder; Respiratory tract disorders; Schizophrenia

Most Recent Events

  • 11 Feb 2009 Discontinued - Phase-I for Anxiety disorders (unspecified route)
  • 11 Feb 2009 Discontinued - Phase-I for Depression (unspecified route)
  • 11 Feb 2009 Discontinued - Phase-I for Schizophrenia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top